Allogene Therapeutics, Inc..
ALLO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) cell therapy for cancer. AlloCAR T™ cell therapy uses engineered immune cells from healthy donors to target and kill cancer cells in patients. Allogene is focused on deve...Show More
Better Health for All
30
Allogene Therapeutics' core business is entirely dedicated to developing allogeneic CAR T-cell therapies for severe conditions like cancer and autoimmune diseases, with 100% of its pipeline focused on potentially revolutionary treatments.
1
The company has received FDA Fast Track Designations for ALLO-329 for lupus, myositis, and scleroderma, and RMAT designations for Cema-Cel (ALLO-501A) for large B-cell lymphoma (LBCL) and ALLO-316 for advanced renal cell carcinoma, indicating significant potential for health benefits.
2
As a clinical-stage company, it has zero harmful products since its inception, with its business model exclusively designed for maximizing global health benefit. The company's R&D expenses were $50.2 million in Q1 2025
3
and $192.3 million in 2024,
4
which constitute 100% of its operating expenses, demonstrating a complete allocation of resources to health innovation. Allogene activates clinical trials at community cancer centers, such as Rocky Mountain Cancer Centers, Arizona Cancer Center, and National Cancer Institute-designated centers, to expand patient access to CAR T therapy, reaching 45-55% of vulnerable populations.
5
The company provides information on risks and benefits of its investigational products through clinical trial data and presentations.
6
While specific adverse event rates are not provided, low rates of CRS and ICANS in Phase 1 trials for cema-cel are mentioned, indicating a proactive safety monitoring approach.
7
The company's Expanded Access policy exists, but no specific details on patent flexibility are provided.
8
Fair Money & Economic Opportunity
0
No evidence available to assess Allogene Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
50
Allogene Therapeutics has an overall employee rating of 4.4 out of 5 stars on Glassdoor, with 85% of employees recommending working at the company and 89% approving of the CEO.
1
The company was also named the highest-ranked biotechnology company and 12th overall in the Bay Area's 2022 "Best Places to Work" list.
2
The voluntary employee turnover rate for Allogene Therapeutics was 0.67%.
3
Fair Trade & Ethical Sourcing
-40
Allogene Therapeutics conducts on-site audits every three years by an external third party to ensure adherence to safety and environmental regulations.
1
Honest & Fair Business
-40
The company has a formal whistleblower policy that allows for anonymous or confidential communication to the Audit Committee regarding accounting, internal controls, or auditing matters.
1
Communications submitted through this channel are required to contain sufficient detail.
2
However, there is no evidence provided regarding independent investigation processes for these communications.
3
Kind to Animals
-40
Allogene Therapeutics conducts extensive in vitro studies using cell lines for cytotoxicity, masking, and protection assays, indicating the use of non-animal testing methods.
1
However, the company also performs animal studies, including using 7- to 9-week-old female NSG mice (n=8 to 10 mice per group) in various xenograft and tumor models,
2
and cynomolgus monkeys for bispecific antibody administration.
3
All animal studies are performed under approval by the Allogene Therapeutics Institutional Animal Care and Use Committee (IACUC).
4
Animals are euthanized when they exhibit disease model-specific endpoints.
5
The company does not source eggs, meat, or dairy.
No War, No Weapons
0
No evidence available to assess Allogene Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
-40
Allogene Therapeutics' Cell Forge 1 facility had one environmental notice of violation in 2022.
1
The company's Code of Business Conduct and Ethics, adopted in October 2024, commits to environmental responsibility, waste reduction, and minimizing hazardous substance use.
2
The company also states its policy to conduct business in an environmentally responsible way that minimizes environmental impacts.
3
The Cell Forge 1 facility, located in Newark, California, earned LEED Gold certification in 2022 and uses 100% carbon-free, renewable energy.
4
Other company sites in South San Francisco utilize electric power from sources that are 50% renewable.
5
The company has implemented water-use reduction devices on bathroom faucets and toilets, a recycling/composting program, and uses compostable materials for crockery at all sites and events.
6
It also removed plastic bottle drinking options and recycles disposable face masks.
7
Respect for Cultures & Communities
0
No evidence available to assess Allogene Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Allogene has no documented data breaches. The company provides compliance training to its employees, with the Compliance Officer responsible for training new employees and conducting annual refreshers.
1
Encryption is implemented as one of the technical and organizational measures to protect personal data.
2
There are no documented incidents of unauthorized data use, and the company pledges to protect personal information, with employees expected to protect data confidentiality and integrity.
3
Users can request access, updates, or deletion of their personal data, and can withdraw consent for processing by contacting the Data Protection Officer.
4
Allogene conducts regular security assessments and continuously reviews and enhances security practices.
5
The company integrates privacy considerations by requiring service providers to protect personal data appropriately and designs clinical trials with high standards of quality and safeguards patient privacy.
6
Data retention is for the period required or allowed by applicable law, or as long as reasonably necessary for the purpose collected.
7
Allogene demonstrates good regulatory compliance, adhering to GAAP, SEC, US export control laws, environmental laws, FDA, ICH GCP, global ethical standards, and data privacy laws including the California Privacy Rights Act, and uses standard contractual clauses for data transfers from the EEA.
8
Zero Waste & Sustainable Products
0
No specific, quantitative evidence was found for Allogene Therapeutics (ALLO.US) regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives with measurable results, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification (e.g., TRUE Zero Waste), waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1
While the company's Cell Forge 1 facility is noted for being fully electric,
2
designed for energy efficiency,
3
water conservation,
4
and reduced greenhouse gas emissions,
5
and aiming for LEED Gold certification,
6
these initiatives primarily relate to energy consumption, emissions, and water conservation, rather than the specific waste and product lifecycle metrics defined under 'Zero Waste & Sustainable Products'.